A human monoclonal antibody blocking SARS-CoV-2 infection

The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19. Vaccines and targeted therapeutics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are currently lacking. Here, the authors report a human monoclonal antibody capable of neutralizing both authentic SARS-CoV and SARS-CoV-2 by targeting a common epitope.

[1]  B. Bosch,et al.  Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections , 2019, Emerging infectious diseases.

[2]  A. M. Leontovich,et al.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.

[3]  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody , 2020, Emerging microbes & infections.

[4]  Haixia Zhou,et al.  Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding , 2016, Cell Research.

[5]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[6]  C. Broder,et al.  Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses , 2009, Expert opinion on biological therapy.

[7]  A. Han,et al.  Universal coronavirus vaccines: the time to start is now , 2020, npj Vaccines.

[8]  Yang Feng,et al.  Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody* , 2006, Journal of Biological Chemistry.

[9]  L. Enjuanes,et al.  Structural Bases of Coronavirus Attachment to Host Aminopeptidase N and Its Inhibition by Neutralizing Antibodies , 2012, PLoS pathogens.

[10]  L. Stamatatos,et al.  Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual , 2020, bioRxiv.

[11]  M. Merad,et al.  Immunology of COVID-19: Current State of the Science , 2020, Immunity.

[12]  B. Bosch,et al.  Cathepsin L Functionally Cleaves the Severe Acute Respiratory Syndrome Coronavirus Class I Fusion Protein Upstream of Rather than Adjacent to the Fusion Peptide , 2008, Journal of Virology.

[13]  Alexander van Oudenaarden,et al.  Publisher Correction: Single-cell and spatial transcriptomics reveal somitogenesis in gastruloids , 2020, Nature.

[14]  M. Wilson,et al.  A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding , 2020, medRxiv.

[15]  William C. Hwang,et al.  Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R* , 2006, Journal of Biological Chemistry.

[16]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[17]  F. Grosveld,et al.  Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein , 2019, Emerging microbes & infections.

[18]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[19]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[20]  Linqi Zhang,et al.  Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27 , 2015, Scientific Reports.

[21]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[22]  R. Baric,et al.  Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge , 2008, Journal of Virology.

[23]  Yi Shi,et al.  Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains , 2017, Nature Communications.

[24]  E. Saphire,et al.  Antibody-mediated protection against Ebola virus , 2018, Nature Immunology.

[25]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[26]  Lisa E. Gralinski,et al.  A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence , 2015, Nature Medicine.

[27]  A. Walls,et al.  Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion , 2019, Cell.

[28]  Jaap Goudsmit,et al.  Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.

[29]  K. Ley,et al.  Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2 , 2020, Trends in Microbiology.